ACE2 and COVID-19: The fact that antibodies binding adjacent to the protease cleavage sites were identified from COVID-19 patients raises the possibility that other mechanism than blocking the RBD-ACE2 interaction could be harnessed for neutralization and might mitigate antibody-dependent enhancement of viral entry.